title: BMP type I receptor inhibition reduces heterotopic [corrected] ossification.
abstract: Fibrodysplasia ossificans progressiva (FOP) is a congenital disorder of progressive and widespread postnatal ossification of soft tissues and is without known effective treatments. Affected individuals harbor conserved mutations in the ACVR1 gene that are thought to cause constitutive activation of the bone morphogenetic protein (BMP) type I receptor, activin receptor-like kinase-2 (ALK2). Here we show that intramuscular expression in the mouse of an inducible transgene encoding constitutively active ALK2 (caALK2), resulting from a glutamine to aspartic acid change at amino acid position 207, leads to ectopic endochondral bone formation, joint fusion and functional impairment, thus phenocopying key aspects of human FOP. A selective inhibitor of BMP type I receptor kinases, LDN-193189 (ref. 6), inhibits activation of the BMP signaling effectors SMAD1, SMAD5 and SMAD8 in tissues expressing caALK2 induced by adenovirus specifying Cre (Ad.Cre). This treatment resulted in a reduction in ectopic ossification and functional impairment. In contrast to localized induction of caALK2 by Ad.Cre (which entails inflammation), global postnatal expression of caALK2 (induced without the use of Ad.Cre and thus without inflammation) does not lead to ectopic ossification. However, if in this context an inflammatory stimulus was provided with a control adenovirus, ectopic bone formation was induced. Like LDN-193189, corticosteroid inhibits ossification in Ad.Cre-injected mutant mice, suggesting caALK2 expression and an inflammatory milieu are both required for the development of ectopic ossification in this model. These results support the role of dysregulated ALK2 kinase activity in the pathogenesis of FOP and suggest that small molecule inhibition of BMP type I receptor activity may be useful in treating FOP and heterotopic ossification syndromes associated with excessive BMP signaling.
authors.forename: Paul B
authors.initials: PB
authors.lastname: Yu
authors.forename: Donna Y
authors.initials: DY
authors.lastname: Deng
authors.forename: Carol S
authors.initials: CS
authors.lastname: Lai
authors.forename: Charles C
authors.initials: CC
authors.lastname: Hong
authors.forename: Gregory D
authors.initials: GD
authors.lastname: Cuny
authors.forename: Mary L
authors.initials: ML
authors.lastname: Bouxsein
authors.forename: Deborah W
authors.initials: DW
authors.lastname: Hong
authors.forename: Patrick M
authors.initials: PM
authors.lastname: McManus
authors.forename: Takenobu
authors.initials: T
authors.lastname: Katagiri
authors.forename: Chetana
authors.initials: C
authors.lastname: Sachidanandan
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kamiya
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Fukuda
authors.forename: Yuji
authors.initials: Y
authors.lastname: Mishina
authors.forename: Randall T
authors.initials: RT
authors.lastname: Peterson
authors.forename: Kenneth D
authors.initials: KD
authors.lastname: Bloch
mesh_terms: D000818:Animals; D052005:Bone Morphogenetic Protein Receptors, Type I / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002460:Cell Line; D004195:Disease Models, Animal; D051379:Mice; D008810:Mice, Inbred C57BL; D015394:Molecular Structure; D009221:Myositis Ossificans / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D009999:Ossification, Heterotopic / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D011720:Pyrazoles / Q000737:chemistry / Q000627:therapeutic use; D011743:Pyrimidines / Q000737:chemistry / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D014057:Tomography, X-Ray Computed
chemical_list: D011720:Pyrazoles; D011743:Pyrimidines; C516138:dorsomorphin; D052005:Bone Morphogenetic Protein Receptors, Type I